表紙:骨関節炎:パイプライン分析
市場調査レポート
商品コード
232841

骨関節炎:パイプライン分析

Osteoarthritis - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 384 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
骨関節炎:パイプライン分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 384 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

骨関節炎は、関節炎で最も一般的なものの1つで、軟骨という、関節を保護する素材が壊れている慢性的な状態を指します。これは骨が互いにすれる原因になり、凝り、痛み、関節の動きの低下につながります。 危険因子には、高齢、関節の怪我、肥満などがあります。 一般的な症候として、関節の痛みや凝り、動かした後に痛みがひどくなる、骨棘、軋むような感覚などがあります。 治療は手、手首、首、背中、ひざ、腰などの損傷を受けた関節の状態によって、薬物療法や運動を行います。

当レポートでは、骨関節炎 の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 骨関節炎 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Abiogen Pharma S.p.A.
  • Ablynx NV
  • Achelios Therapeutics, Inc.
  • Addex Therapeutics Ltd
  • Akari Therapeutics, Plc
  • Amura Holdings Limited
  • Arcarios BV
  • 旭化成ファーマ
  • Asklepios BioPharmaceutical, Inc.
  • アステラス製薬
  • Asterias Biotherapeutics, Inc.
  • Axsome Therapeutics, Inc.
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd.
  • Cara Therapeutics, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Evgen Pharma PLC
  • Galapagos NV
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • IntelliCell BioSciences Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • K-Stemcell Co., Ltd.
  • Levolta Pharmaceuticals, Inc.
  • Medivir AB
  • Merck KGaA
  • Mesoblast Limited
  • Mor Research Application Ltd
  • NicOx S.A.
  • Nordic Bioscience A/S
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • Omeros Corporation
  • 小野薬品工業
  • OrthoCyte Corporation
  • Osteologix Holdings Plc
  • Pfizer Inc.
  • Pharmalink AB
  • PLx Pharma Inc.
  • ProteoThera, Inc.
  • Regeneus Ltd
  • ReqMed Company, Ltd.
  • Sanofi
  • 生化学工業
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • STELIS Biopharma Pvt. Ltd.
  • Stempeutics Research Private Limited
  • Symic Biomedical, Inc.
  • 武田薬品工業
  • TissueGene, Inc.
  • Upsher-Smith Laboratories, Inc.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Yuhan Corporation
  • Yungjin Pharm. Co., Ltd.
  • Zimmer Biomet Holdings, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (apocynin + paeonol)
  • (clodronate disodium + hyaluronic acid)
  • ABT-981
  • AlloJoin
  • AM-3701
  • AM-3876
  • Anatabine
  • 骨関節炎向け阻害剤
  • 骨関節炎向け TGF-β1阻害抗体
  • ARC-118
  • AS-001
  • ASP-7962
  • BNP-OA
  • BRM-421
  • CDX-085
  • celecoxib
  • CHND-1
  • CKD-941
  • clodronate disodium
  • CR-8357
  • CR-845
  • CRB-0017
  • CS-30MS02
  • DA-5202
  • DIS-BIO-EPS
  • DNX-314
  • 骨疾患・骨関節炎治療薬
  • 骨関節炎治療薬
  • 骨関節炎向けレニン・アンギオテンシン阻害薬
  • 骨関節炎・骨折向け骨形成タンパク質調整薬
  • 免疫学・代謝性疾患・筋骨格障害向けPPAR-δ調整薬
  • duloxetine hydrochloride DR
  • fasitibant chloride
  • GLPG-1972
  • GQ-203
  • GQ-303
  • GSK-2394002
  • GZ-389988
  • JD-4000 Series
  • Kartogenin
  • KBP-056
  • ketoprofen
  • KM-278
  • LEVI-04
  • LH-023
  • LNA-043
  • MIV-711
  • 炎症性疾患・骨関節炎向けモノクローナル抗体
  • 骨関節炎向けモノクローナル阻害剤
  • MOR-106
  • MSBCAR-001
  • naproxcinod
  • NBS-101
  • NStride APS
  • OAX-1
  • ONO-4474
  • OTXCP-03
  • OTXCP-07
  • ペントサン多硫酸ナトリウム
  • 骨関節炎向けペプチド
  • piclidenoson
  • PL-1100
  • PRO-1
  • Progenza
  • 骨関節炎向けタンパク質
  • 骨関節炎・喘息向けタンパク質
  • リウマチ性関節炎・骨関節炎向けタンパク質
  • 肥満・骨関節炎・腎線維症・アルポート症候群向け BMP-7活性タンパク質
  • PRX-167700
  • 骨関節炎向け組換ペプチド
  • 骨関節炎・中枢神経向けIL-4/IL-10受容体活性組換タンパク質
  • 骨関節炎向けIGF-1受容体作動組換タンパク質
  • 骨粗しょう症・骨関節炎向けPTH受容体作動組換タンパク質
  • ReJoin
  • Salmon Calcitonin
  • SAR-396049
  • SB-061
  • SBL-005
  • SI-613
  • SM-04690
  • 変性性関節炎向け小分子
  • 骨関節炎向け小分子
  • 免疫学・血液学・神経疾患向けA2A作動薬
  • 骨関節炎向けMMP13阻害剤
  • 不安症・循環器疾患・骨関節炎GPR22標的薬
  • 免疫学・代謝障害・筋骨格障害向け小分子
  • 免疫学・筋骨格障害・代謝障害向け小分子
  • 骨関節炎向け小分子
  • 免疫学・胃腸障害・神経学・血液疾患向けTNFR1拮抗薬
  • 骨関節炎向けADAMTS-5阻害剤
  • 骨関節炎向け補体系タンパク質阻害剤
  • 骨関節炎・骨粗しょう症向けキナーゼ阻害剤
  • 骨関節炎向けMMP-13阻害剤
  • sprifermin
  • 自己免疫疾患向け幹細胞療法
  • 中枢神経・CVS・皮膚疾患・免疫疾患ん・代謝障害向け幹細胞療法
  • 変性性関節炎向け幹細胞療法
  • 膝関節炎向け幹細胞療法
  • 多発性硬化症・リウマチ性関節炎・骨関節炎・自閉症・気管支肺異形成症・心不全・脳性まひ向け幹細胞療法
  • 骨関節炎向け幹細胞療法
  • 骨関節炎・真性糖尿病・急性肝不全心肺機能蘇生後疾患・神経変性病向け幹細胞療法
  • Stempeucel
  • 関節炎向け間質細胞療法
  • Sulforadex
  • tonogenchoncel-L
  • TPX-100
  • TRBN-0224
  • UGP-302
  • VOLT-01
  • X-0002
  • XT-101
  • XT-150
  • YH-14619
  • YRA-1909
  • YY-1201
  • zoledronic acid
  • ZYN-002
  • ■最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Osteoarthritis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Osteoarthritis - Pipeline by 4P-Pharma SAS, H2 2020
  • Osteoarthritis - Pipeline by Abiogen Pharma SpA, H2 2020
  • Osteoarthritis - Pipeline by Ablynx NV, H2 2020
  • Osteoarthritis - Pipeline by Aclaris Therapeutics Inc, H2 2020
  • Osteoarthritis - Pipeline by Adare Pharmaceuticals Inc, H2 2020
  • Osteoarthritis - Dormant Projects, H2 2020
  • Osteoarthritis - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Osteoarthritis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
目次
Product Code: GMDHC12484IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2020, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 23, 21, 1, 1, 56, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 7 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Osteoarthritis - Overview
  • Osteoarthritis - Therapeutics Development
  • Osteoarthritis - Therapeutics Assessment
  • Osteoarthritis - Companies Involved in Therapeutics Development
  • Osteoarthritis - Drug Profiles
  • Osteoarthritis - Dormant Projects
  • Osteoarthritis - Discontinued Products
  • Osteoarthritis - Product Development Milestones
  • Appendix